NMS · Biotechnology

Spero Therapeutics, Inc. (SPRO) Stock

$1.22 +1.67% NMS: SPRO Healthcare

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States.

Valuation

MetricValue
Price$1.22
Market Cap$70.64M
P/E Ratio16.13
P/B Ratio2.37
P/S Ratio2.83
EPS (TTM)$0.15
52-Week High$3.08
52-Week Low$1.08
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE15.25%
ROA13.04%
ROCE0.00%
Gross Margin0.00%
Operating Margin24.66%
Net Margin27.82%
Debt/Equity0.05
Current Ratio7.44

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$49.0M$104.0M$48.0M$60.0M
Operating Profit$-88.0M$-42.0M$21.0M$-73.0M$0
Net Profit$-90.0M$-46.0M$23.0M$-69.0M$9.0M
EPS$-2.91$-1.23$0.43$-1.27$0.15
Op Margin-2865.5%-86.9%20.7%-152.9%-0.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$171.0M$125.0M$182.0M$111.0M$69.0M
Total Liabilities$83.0M$49.0M$75.0M$64.0M$10.0M
Cash$113.0M$109.0M$76.0M$53.0M$40.0M
Borrowings$7.0M$7.0M$6.0M$4.0M$3.0M

Latest News

Sector Update: Healthcare Stocks Mixed Premarket Tuesday MT Newswires · Jul 14, 2026 Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing MT Newswires · Jul 14, 2026 Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) InvestorsHub · Jul 14, 2026 Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties GlobeNewswire · Jul 14, 2026 Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M
Investing Cash Flow$8.0M$34.0M$0$0$0
Financing Cash Flow$47.0M$0$0$0$0
Net Cash Flow$27.0M$-3.0M$-33.0M$-23.0M$-13.0M
Free Cash Flow$-64.0M$-8.0M$-33.0M$-23.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA2.85
FCF Yield27.72%
Quick Ratio6.12
Interest Coverage0.00
Return 1Y-33.53%
Return 3Y9.60%
Return 5Y-88.53%

Ownership

Insiders Held22.46%
Institutions Held16.16%
Institutions Float Held20.84%
Institutional HolderSharesReport Date
GSK plc9,190,6062026-03-31
Pfizer Inc2,362,3482026-03-31
Vanguard Capital Management LLC1,799,8802026-03-31
Renaissance Technologies, LLC1,189,2352026-03-31
Alphabet Inc.889,9792026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $3.10 +6.16% -1.17 $223.91M 0.00%
ACTU $1.30 -15.58% -2.73 $31.10M 0.00%
CGTX $1.05 +3.96% -3.94 $93.97M 0.00%
CRBP $11.48 +1.77% -1.95 $212.70M 0.00%
HURA $2.09 +2.96% -3.75 $133.10M 0.00%

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Spero Therapeutics, Inc. is led by CEO Esther Rajavelu, employs 32 people, headquartered in US, publicly traded since 2017.

Spero Therapeutics, Inc. (SPRO) stock trades at $1.22 with a market capitalization of $70.64M. The stock is valued at a price-to-earnings (P/E) ratio of 16.13, price-to-book of 2.37, price-to-sales of 2.83. Over the past 52 weeks the stock has ranged between $1.08 and $3.08, and currently trades 60.4% below its 52-week high.

On profitability, Spero Therapeutics, Inc. generates a return on equity (ROE) of 15.25%, above the typical market average, return on capital employed of 0.00%, an operating margin of 24.66%, a net profit margin of 27.82%.

Official website: sperotherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.75 +3.62% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides